Innovotech Inc.

Innovotech Inc.

August 18, 2010 06:00 ET

Innovotech Reports Second Quarter 2010 Financial Results

EDMONTON, ALBERTA--(Marketwire - Aug. 18, 2010) - Innovotech Inc. (TSX VENTURE:IOT), a pioneer in the field of biofilm product development, today announced its unaudited financial and operational results for the three and six-month periods ended June 30, 2010.


    Revenue for first half of 2010 up 46% over 2009
    Innovotech receives funding from Agriculture and Agri-Foods Canada to facilitate commercialization of Agress™
    Extensive 2010 field trial season for Agress™

"Innovotech continues to see a demand for its expertise and technology as demonstrated by the increase in revenue for the first half of the year compared with the same period for 2009" said Dr. James Timourian, Chief Financial Officer. "The increase was largely due to significant growth in contract research revenue and is indicative of the increasing awareness of the role biofilms play in the world. We expect the revenue growth in contract research to continue."

The Company has been awarded funding in excess of $900,000 from Agriculture and Agri-Food Canada to facilitate the commercialization of Agress™, its unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections. The two-year, repayable funding will focus on field trials to expand the potential applications of Agress™ from pulse crops (dry beans, dry peas, lentils, chickpeas) and soybeans to high value horticultural crops such as tomatoes, peppers, and potatoes. The funding will also be used to support regulatory approval submissions for Agress™.

The Agress ™ 2010 crop season marks the most aggressive and diverse field trial season to date for both Innovotech and its partner, Syngenta. Field testing is occurring in both bacterial and fungal diseases, and in foliar sprays and seed treatments. So far, Agress™ has met or exceeded expectations. Innovotech test crops include potatoes, tomatoes, brassica (broccoli, cauliflower) vegetables, dry beans, and chickpeas. In addition, Syngenta has extensive field trials occurring in Canada, United States and Europe.

There is growing international recognition that the Company's test kit bioFILM PA™ can save lives and reduce health care costs. Subsequent to the second quarter, the Company has signed a distribution agreement for bioFILM PA™ with LevPharm Ltd. to serve the Israeli market and is looking to expand its availability to counter cystic fibrosis, pneumonia, burn and other stubborn bacterial infections at home in Canada as well as elsewhere in the world. There are 35 million susceptibility tests performed each year worldwide, and bioFILM PA™ can replace many of them with more effective results.

Financial Summary

($) Three-month period ended 30 June 2010     Three-month period ended 30 June 2009     Six-month period ended 30 June 2010     Six-month period ended 30 June 2009  
Revenues 408,288     373,697     862,658     589,698  
G&A 279,268     251,096     610,732     497,132  
R&D 195,140     208,857     345,558     401,007  
Net loss (261,831 )   (287,551 )   (491,910 )   (654,821 )
Share Price -     -     $.66     $.80  
Cash -     -     1,203,433     1,773,452  

About Innovotech Inc.:

Innovotech Inc. is a pioneer in the field of biofilm product development, focused on providing innovative and practical solutions to medical, agricultural and industrial problems caused by microbial biofilms. Biofilms are responsible or a host of diseases in both agriculture and human health due to their inherent resistance to existing antibiotics and disinfectants. There are currently no antibiotics, disinfectants, diagnostics or regulatory standards designed specifically for biofilm-forming organisms.

Innovotech currently has two products in advanced stages of development: Agress™ a unique, environmentally friendly seed treatment and plant spray designed to protect crops against both bacterial and fungal infections, and bioFILM PA™, the first diagnostic kit to assist physicians in the selection of the most effective combination of antibiotic treatment of patients with biofilm-based chronic lung infections.

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information